The Antibody Production Market to Be Worth $58.35 Billion by 2031 by Meticulous Research®

According to a new market research report titled, 'Antibody Production Market by Product [Bioreactors (Single use, Reusable), Chromatography, Filtration, Cell Lines, Media, Buffers, Resins], Antibody [Monoclonal, Polyclonal], Source [Mice, Rabbit], Process [Downstream, Upstream] - Global Forecast to 2031,' published by Meticulous Research®, the antibody production market is expected to grow at a CAGR of 11.4% from 2024 to reach $58.35 billion by 2031.

Download Free Sample Report Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=5769

There is an increasing demand for antibodies as they are used in therapeutics as well as in diagnostic applications. The commercial use of antibodies needs manufacturing at a large amount which is achieved by instruments such as bioreactors, chromatography systems, filtration systems, and other instruments. Downstream and upstream processes are used for antibody production. These antibodies can be obtained from various sources, such as mice, rabbits, goat, sheep, and chicken, among others.

The growth of the global antibody production market is attributed to the growing demand for targeted antibodies, increasing investments in R&D by pharma & biotech companies, high burden and growing prevalence of cancer and autoimmune diseases, increasing use of immunoassays, and advancements in bioprocessing technologies. Moreover, growing applications of antibodies in clinical trials and medical research, significant opportunities from developing countries, growing risk and prevalence of infectious diseases offer market growth opportunities.

Increasing R&D Investments by Pharma & Biotech Companies Drive the Antibody Production Market

Pharmaceutical and biotech companies are heavily investing in research and development with a focus on developing novel drugs, drug molecules, and biologics. For instance, according to the PhRMA (Pharmaceutical Research and Manufacturers of America) annual membership survey 2022, the R&D spending of PhRMA member companies in the U.S. pharmaceutical & biopharmaceutical sector reached USD 102.3 billion in 2021, a significant increase over USD 83.0 billion in 2019. Similarly, according to PhRMA & the National Venture Capital Association, venture capital investments from established biopharmaceutical companies in emerging biotechnology firms from the U.S. to support R&D increased from USD 11 billion in 2015 to USD 15 billion in 2020.

Quick Buy @ https://www.meticulousresearch.com/Checkout/94986614

Research and development aids in the identification and validation of new biologics, including antibodies for therapeutic applications, therefore, such investments in R&D are expected to lead to the development of new antibodies, which will boost their production for therapeutic purposes.
The key players profiled in this market study are Thermo Fisher Scientific Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Merck KgaA (Germany), Eppendorf SE (Germany), Sartorius AG (Germany), Danaher Corporation (U.S.), Waters Corporation (U.S.), Shimadzu Corporation (Japan), Solaris Biotechnology Srl (Italy), and Infors AG (Switzerland). The report also includes an extensive assessment of the product portfolios, geographic presence, and key strategic developments of the leading market participants over the past years. The antibody production market has recently witnessed several new product launches and enhancements.

The global antibody production market is segmented by product (instruments [bioreactors {reusable bioreactors, single-use bioreactors}, chromatography systems, filtration system, and other instruments], consumables {cell lines & media, buffers & reagents, chromatography columns & resins, and other consumables}), antibody type {monoclonal antibodies, polyclonal antibodies, and, recombinant antibodies}, by source {mice, rabbit, and other sources}, by process {downstream and upstream}, end user {pharmaceutical & biotechnology companies, clinical research organizations and contract development & manufacturing organizations, academic & research institutes}) and geography. The study also evaluates industry competitors and analyzes the market at the regional and country levels.

Based on product, the antibody production market is segmented into instruments, consumables, and software. In 2024, the instruments segment is expected to account for the largest share of the market. The need for high volume production of antibodies and large scale of production for commercial use, the need for separation of purification and isolation of antibodies, and the growing need for mass production of antibodies for therapeutic applications are the major factors attributed to the large segment share. Antibodies are used for several applications, including targeted treatment for cancer, infectious diseases, and other disorders. For commercial sale and use of antibodies, they need to be manufactured on a large scale; instruments such as bioreactors and chromatography systems enable large-scale production and purification of antibodies, making them suitable for commercial use, leading to the large share of the instruments segment in the antibody production market.

Based on antibody type, the antibody production market is segmented into monoclonal antibodies, polyclonal antibodies, antibody segments, and recombinant antibodies. In 2024, the monoclonal antibodies segment is expected to account for the largest share of the market. The large segment can be attributed to the growing demand for targeted therapy for cancer and supporting initiatives for the development and identification of new antibodies for therapeutics and getting approvals. For instance, in targeted immunotherapy for cancer, targeted monoclonal antibodies are used as a form of cancer immunotherapy treatment that can disrupt cancer cell activity and alert the immune system to target and eliminate cancer cells. Most targeted monoclonal antibodies target cancer cells directly rather than targeting immune cells, leading to their demand for cancer treatment. Therefore, the growing demand for targeted cancer therapy coupled with high cancer prevalence is one of the leading factors for the large share of this segment.

Based on source, the antibody production market is segmented into mice, rabbit, and other sources. In 2024, the mice segment is expected to account for the largest share of the market. This large share is attributed to the ready availability, low cost, short production times for mouse antibodies, ease of mouse husbandry, and the genetic approaches to engineering antibodies through recombinant technologies that are more established for mice.

Based on process, the antibody production market is segmented into upstream and downstream. In 2024, the downstream segment is expected to account for the largest share of the market. This large share can be attributed to the high preference for downstream processing and the growing demand for antibody-based therapeutics.

Based on end user, the antibody production market is segmented into pharmaceutical & biotechnology companies, clinical research organizations and contract development & manufacturing organizations, and other end users. The pharmaceutical & biotechnology companies segment is expected to grow at the highest CAGR during the forecast period. The major factors attributed to this growth are the expansion of antibody manufacturing facilitates, increasing R&D investments by pharma & biotech companies, the growing prevalence of chronic and infectious diseases, and the need for the development of antibody-based therapeutics for these diseases. In addition to that, the capacity and geographic expansion of production facilities by the pharmaceutical and biopharmaceutical companies is further expected to drive the segment growth. For instance, in 2021, Merck KGaA (Germany) announced an investment of USD 174 million for a new production facility in France. This facility is involved in the production of commercial monoclonal antibody drug substances.

North America is expected to dominate the antibody production market in 2023, followed by Europe and Asia-Pacific. Increasing R&D expenditure by the pharmaceutical & biotechnology industry, technological advancements in bioprocessing, the high number of industry-academia collaborations for research and development of antibodies, the high prevalence of chronic diseases, and the high demand for biologics are expected to support North America's largest share.

To gain more insights into the market with a detailed table of content and figures, click here: @ https://www.meticulousresearch.com/product/antibody-production-market-5769

Scope of the Report:
Antibody Production Market Assessment, by Product
• Instruments
o Bioreactors
 Single-use bioreactors
 Reusable Bioreactors
o Chromatography Systems
o Filtration Systems
o Other Instruments
(Other Instruments include Shakers, mixers, incubators, sterilizers, centrifuge, and bioprocessing containers, among others)
• Consumables
o Cell Lines & Media
o Buffers & Reagents
o Chromatography Columns & Resins
o Other Consumables
(Other Instruments include Shakers, mixers, incubators, sterilizers, centrifuge, and bioprocessing containers, among others)
• Software

Antibody Production Market Assessment, by Antibody Type
• Monoclonal antibodies
• Polyclonal Antibodies
• Recombinant Antibodies

Antibody Production Market Assessment, by Source
• Mice
• Rabbit
• Other Sources
(Other sources include goat, sheep, and chicken, among others)

Antibody Production Market Assessment, by Process
• Downstream
• Upstream

Antibody Production Market Assessment, by End User
• Pharmaceutical & Biotechnology Companies
• Clinical Research Organizations & Contract Development & Manufacturing Organizations
• Academic & research Institutes

Antibody Production Market Assessment, by Geography
• North America
o U.S.
o Canada
• Europe
o Germany
o France
o U.K.
o Italy
o Spain
o Rest of Europe (RoE)
• Asia-Pacific (APAC)
o Japan
o China
o India
o Rest of APAC (RoAPAC)
• Latin America
o Brazil
o Mexico
o Rest of Latin America (RoLATAM)
• Middle East & Africa

About Us
We are the trusted research partners for leading businesses around the world, providing market intelligence focused towards building revenue transformation strategies. Our research is used by Fortune 500 organizations to attain success by scouting next generation revenue opportunities well ahead of their competition.

Address
Office No-202, 203,204,205,206
2nd Floor, Pushpak Business Hub,
Wakad, Pimpri-Chinchwad,
411057, India.

This release was published on openPR.